CIK 0000875045
- Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330112644
- Phone
- +1 617-679-2000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Option exercise | +1,965 | 8,751.19 | ||
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Shares withheld for taxes | −873 | $319.43 | $279K | 7,878.19 |
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Option exercise | +1,574 | 9,452.19 | ||
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Shares withheld for taxes | −699 | $319.43 | $223K | 8,753.19 |
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Grant or award · Restricted Stock Unit | +10,330 | 10,330 | ||
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −1,104 | 2,211 | ||
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −1,965 | 1,453 | ||
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Other disposition · Restricted Stock Unit | −1,453 | 0 | ||
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −1,574 | 6,716 | ||
| 2019-02-12 | Sandrock Alfred EVP, Chief Medical Officer | Other disposition · Restricted Stock Unit | −1,188 | 5,528 | ||
| 2019-02-12 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Option exercise | +1,263 | 5,639.63 | ||
| 2019-02-12 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Shares withheld for taxes | −380 | $319.43 | $121K | 5,259.63 |
| 2019-02-12 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Option exercise | +1,799 | 7,058.63 | ||
| 2019-02-12 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Shares withheld for taxes | −539 | $319.43 | $172K | 6,519.63 |
| 2019-02-12 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Option exercise · Restricted Stock Unit | −1,263 | 2,527 | ||
| 2019-02-12 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Option exercise · Restricted Stock Unit | −1,799 | 7,671 | ||
| 2019-02-12 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Other disposition · Restricted Stock Unit | −1,357 | 6,314 | ||
| 2019-02-12 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Grant or award · Restricted Stock Unit | +10,960 | 10,960 | ||
| 2019-02-12 | Kramer Robin VP, Chief Accounting Officer | Grant or award · Restricted Stock Unit | +860 | 860 | ||
| 2019-02-12 | Karp Daniel EVP, Corporate Development | Grant or award · Restricted Stock Unit | +6,260 | 6,260 |
Page 52 of 61 · 1,204 trades